NO20042822L - Forlenget frigjoring - farmasoytisk tablett av metformin - Google Patents

Forlenget frigjoring - farmasoytisk tablett av metformin

Info

Publication number
NO20042822L
NO20042822L NO20042822A NO20042822A NO20042822L NO 20042822 L NO20042822 L NO 20042822L NO 20042822 A NO20042822 A NO 20042822A NO 20042822 A NO20042822 A NO 20042822A NO 20042822 L NO20042822 L NO 20042822L
Authority
NO
Norway
Prior art keywords
metformin
extended release
released
hours
pharmaceutical tablet
Prior art date
Application number
NO20042822A
Other languages
English (en)
Other versions
NO333929B1 (no
Inventor
Benoit Schmitt
Pawan Seth
Original Assignee
Valeant Internat Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Internat Bermuda filed Critical Valeant Internat Bermuda
Publication of NO20042822L publication Critical patent/NO20042822L/no
Publication of NO333929B1 publication Critical patent/NO333929B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20042822A 2001-12-04 2004-07-02 Forlenget frigjøring - farmasøytisk tablett av metformin NO333929B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/005,387 US20030118647A1 (en) 2001-12-04 2001-12-04 Extended release tablet of metformin
PCT/US2002/038599 WO2003047529A2 (en) 2001-12-04 2002-12-04 Extended release pharmaceutical tablet of metformin

Publications (2)

Publication Number Publication Date
NO20042822L true NO20042822L (no) 2004-08-26
NO333929B1 NO333929B1 (no) 2013-10-21

Family

ID=21715581

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20042822A NO333929B1 (no) 2001-12-04 2004-07-02 Forlenget frigjøring - farmasøytisk tablett av metformin
NO20130984A NO20130984L (no) 2001-12-04 2013-07-16 Forlenget frigjøring - farmasøytisk tablett av metformin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20130984A NO20130984L (no) 2001-12-04 2013-07-16 Forlenget frigjøring - farmasøytisk tablett av metformin

Country Status (12)

Country Link
US (3) US20030118647A1 (no)
EP (1) EP1460998B1 (no)
AT (1) ATE460157T1 (no)
AU (1) AU2002359582C1 (no)
CA (1) CA2470747C (no)
DE (1) DE60235648D1 (no)
ES (1) ES2338536T3 (no)
HU (1) HU229962B1 (no)
MX (1) MXPA04005667A (no)
NO (2) NO333929B1 (no)
NZ (1) NZ533857A (no)
WO (1) WO2003047529A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000273085A1 (en) * 2000-10-02 2002-04-15 Usv Limited Sustained release pharmaceutical compositions containing metformin and method ofits production
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20080181946A1 (en) * 2004-05-14 2008-07-31 Braj Bhushan Lohray Controlled Release Delivery System For Metformin
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
KR100858848B1 (ko) * 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
RS55769B1 (sr) * 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
CA2994873A1 (en) * 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN103622930B (zh) * 2013-12-19 2015-06-10 石家庄市华新药业有限责任公司 一种盐酸二甲双胍缓释制剂及其制备方法
WO2016042567A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of metformin
JP7152114B2 (ja) * 2018-03-29 2022-10-12 タタ ケミカルズ リミテッド 食用塩組成物の強化用のカプセル化された微量栄養素顆粒

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2001A (en) * 1841-03-12 Sawmill
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CH672888A5 (no) * 1986-11-07 1990-01-15 Mepha Ag
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
ATE286394T1 (de) * 1995-09-21 2005-01-15 Pharma Pass Ii Llc Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
DE19915420A1 (de) * 1999-04-06 2000-10-12 Basf Ag Stabilisierte Polyvinylpyrrolidon-Zubereitungen
US6338857B1 (en) * 2000-05-26 2002-01-15 Pharma Pass Llc Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
EP1460998A2 (en) 2004-09-29
NZ533857A (en) 2007-05-31
CA2470747A1 (en) 2003-06-12
AU2002359582A1 (en) 2003-06-17
AU2002359582C1 (en) 2008-11-13
AU2002359582B2 (en) 2007-01-18
ES2338536T3 (es) 2010-05-10
DE60235648D1 (de) 2010-04-22
NO333929B1 (no) 2013-10-21
HUP0500004A2 (hu) 2005-04-28
WO2003047529A2 (en) 2003-06-12
US20030118647A1 (en) 2003-06-26
WO2003047529A3 (en) 2003-10-30
ATE460157T1 (de) 2010-03-15
EP1460998A4 (en) 2005-09-14
NO20130984L (no) 2004-08-26
HU229962B1 (hu) 2015-03-30
US20040161461A1 (en) 2004-08-19
HUP0500004A3 (en) 2012-09-28
EP1460998B1 (en) 2010-03-10
CA2470747C (en) 2009-07-28
MXPA04005667A (es) 2005-06-17
US20030170302A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
NO20042822L (no) Forlenget frigjoring - farmasoytisk tablett av metformin
BR9908438A (pt) Tabletes de desintegração rápida
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
SE9704869D0 (sv) New pharmaceutical formulaton II
WO2003072025A3 (en) Modified release formulations of at least one form of tramadol
DK1239857T3 (da) Dual-release-præparater af en cyclooxygenase-2-hæmmer
DOP2013000023A (es) Un compuesto seleccionado del acido 6-(4-bromo-2-cloro-fenilamino) -7-fluror-3-metil-3h-benzoimidazol -5-carboxilico (2-hidroxi-etoxi)-amida y sales farmaceuticamente aceptables del mismo, y composiciones farmaceuticas que contienen dicho compuesto
HRP20040996B1 (hr) Tablete visokog sadržaja lijeka
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
NO971206D0 (no) Forlenget-frigjöringsformulering
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
DK1113787T3 (da) Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling
ATE321537T1 (de) Pharmazeutische zubereitung enthaltend doxazosin
IS2691B (is) Áætlun um lyfjaskammta og lyfjasamsetningar til getnaðarvarnar í neyð
GB0012362D0 (en) Chemical compounds
EP1678162A4 (en) P-GLYCOPROTEIN INHIBITOR, METHOD OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
AR036658A1 (es) Formulacion de dosificacion oral de fundicion instantanea
IS2347B (is) Lyfjablanda til inntöku um munn sem felur í sér jóta-karragen, eina eða fleiri hlutlausar hlaupkenndar fjölliður og basískan lyfjafræðilegan efnisþátt; þar sem blandan tálmar losun basíska lyfjafræðilega virka efnisþáttarins úr blöndunni við súrt pH-
AR014012A1 (es) Formula de liberacion prolongada
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form
MXPA04007437A (es) Sistema de suministro osmotico.
NO996049D0 (no) Kontrollert-frigjøring farmasoeytisk preparat med ACE inhibitor som aktivt middel
WO2003041656A3 (en) Soluble drug extended release system

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VALEANT INTERNATIONAL BERMUD, BM

MM1K Lapsed by not paying the annual fees